Please use this identifier to cite or link to this item:
|Title:||Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.||Austin Authors:||Richter, Suzanne;Seah, Jo-An;Pond, Gregory R;Gan, Hui K ;Mackenzie, Mary J;Hotte, Sebastien J;Mukherjee, Som D;Murray, Nevin;Kollmannsberger, Christian;Heng, Daniel;Haider, Masoom A;Halford, Robert;Ivy, S Percy;Moore, Malcolm J;Sridhar, Srikala S||Affiliation:||Austin Health, Ludwig Institute for Cancer Research, Melbourne, Australia
McMaster University, Hamilton, ON;
London Region Cancer Program, Western University, London, ON;
Juravinski Cancer Centre, McMaster University, Hamilton, ON;
BC Cancer Agency, University of British Columbia, Vancouver, BC;
Tom Baker Cancer Centre, University of Alberta, Calgary, AB;
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON;
Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD.
Princess Margaret Cancer Centre, Toronto, ON;
|Issue Date:||1-Nov-2014||Publication information:||Canadian Urological Association Journal = Journal De L'association Des Urologues Du Canada; 8(11-12): 398-402||Abstract:||Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to second-line therapy, however, remain more controversial with respect to drug selection and drug sequencing.In this study we evaluated mRCC patients who were initially treated on the first-line National Cancer Institute (NCI) trial with the highly potent vascular endothelial growth factor receptor tyrosine kinase inhibitor (TKI), cediranib, to determine the efficacy and tolerability of subsequent therapies.Twenty-eight (65.1%) of the 43 patients enrolled on the first-line cediranib trial were known to receive second-line therapy, most commonly sunitinib (n = 21), with 4 (14%), 2 (7%) and 1 (3%) patients receiving temsirolimus, sorafenib, and interleukin, respectively. Of these, 14 (50%) went on to have 3 or more lines of therapy. The progression-free survival (PFS) proportion (PFS) at 1 year from starting second line was 30% (14.5%-47.9%). Longer duration of first-line cediranib treatment was modestly associated with longer duration of second-line treatment (Spearman rho 0.26). Patients who discontinued cediranib for toxicity were less likely to receive second-line sunitinib.In this real world evaluation, sequential use of TKIs for the management of mRCC was common. PFS with sequential TKIs was similar to observed and published results for any second-line therapy. Prior toxicity affected treatment patterns and the frequent use of at least 3 lines of therapy underscores the need for prospective sequencing trials in this disease.||Gov't Doc #:||25553152||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12552||DOI:||10.5489/cuaj.2426||URL:||https://pubmed.ncbi.nlm.nih.gov/25553152||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.